Mycronic AbOMXSTO: MYCR

MYCR: Record sales, strong margins, and increased dividend highlight robust performance and outlook

· Issued by Mycronic Ab

Record Q4 and full-year results with strong sales, order intake, and EBIT margin. All divisions exceeded margin targets, and significant investments in R&D and sales network are planned for 2025. Dividend increased, with continued focus on both organic growth and M&A.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.